ANL
Adlai Nortye Ltd.
NASDAQ · Healthcare · Biotechnology · KY
$10.38
−5.89%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$10.97
From 52W high−37.47%
Volume356262.00
Market cap$668.45M
P/E (TTM)—
P/S (TTM)34.0x
Div yield—
Key dataOct 19, 2026
Open
$10.97
From 52W high
−37.47%
Volume
356262.00
Market cap
$668.45M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−22.0x
P/E (TTM)
—
RSI (14)
35.9
MomentumView details →
1D Return
−5.89%
YTD Return
+693.66%
SummaryUpdated Jun 1, 2026
Adlai Nortye Ltd. (NASDAQ:ANL) is a clinical-stage biotechnology company founded in 2018 and incorporated in the Cayman Islands. The company went public in September 2023 and focuses on discovering and developing innovative cancer therapies for patients in the United States and Mainland China. As a relatively young biotech firm, Adlai Nortye is currently in the clinical development phase with its lead drug candidate progressing through Phase III trials, while maintaining a robust pipeline of preclinical and early-stage therapeutic programs targeting various cancer pathways.
Similar companies
Latest newsMore news →
Adlai Nortye Ltd. entered into a clinical collaboration with Eli Lilly and Merck KGaA to evaluate AN4035 as monotherapy and in combination with cetuximab in an ongoing global Phase I trial.5d agoAdlai Nortye dosed the first patient in Australia and received U.S. FDA IND clearance for AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC targeting CEACAM5, initiating a global Phase I trial.42d ago